Pharmacological management of pancreatitis.
Pancreatitis is a common disease with substantial morbidity and mortality. Pharmacological therapy for the prevention and treatment of pancreatitis is an intense subject of investigation. The use of proteinase inhibitors such as gabexate mesylate in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis (ERCP) has been disappointing. Initial studies using ulinastatin are promising but additional dose-response studies are needed. Somatostatin, but not octreotide, is likely to be effective in the prevention of post-ERCP pancreatitis. Rectal diclofenac might provide a simple, cheap alternative but large-scale studies are again needed. New insights into the role of proteinase-activated receptor-2 in the pancreas add to the complexity of the mechanisms involved in the pathophysiology of pancreatitis, and the development of specific agonists and antagonists of this receptor is necessary to assess their therapeutic potential in the prevention and management of pancreatitis.
Hoogerwerf
Willemijntje A
WA
University of Texas Medical Branch, Division of Gastroenterology, Galveston, Texas 77555-0764, USA. wahooger@utmb.edu
D000818:Animals; D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000009:adverse effects; D016670:Gabexate / Q000627:therapeutic use; D006023:Glycoproteins / Q000627:therapeutic use; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy; D010195:Pancreatitis / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D011480:Protease Inhibitors / Q000627:therapeutic use; D044464:Receptor, PAR-2 / Q000502:physiology; D013004:Somatostatin / Q000627:therapeutic use
D006023:Glycoproteins; D011480:Protease Inhibitors; D044464:Receptor, PAR-2; D016670:Gabexate; D013004:Somatostatin; C028665:urinastatin; D015282:Octreotide